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 Highlights 
• Vitamin D deficiency has been identified as a potential risk factor for cardiovascular 
disease. 
• Review of RCTs of effects of vitamin D supplementation on endothelial 
function/inflammation. 
• 8/29 studies reported improvements in the endothelial/inflammatory parameters measured. 
• This review does not support use of vitamin D as a preventative measure for CVD. 
 
 Abstract 
This systematic review aims to evaluate randomised controlled trials (RCTs) investigating the 
effect of vitamin D supplementation on endothelial function and inflammation in adults.  An 
electronic search of published randomised controlled trials, using Cochrane, Pubmed and 
Medline databases was conducted, with the search terms related to vitamin D and endothelial 
function. Inclusion criteria were RCTs in adult humans with a measure of vitamin D status 
using serum/plasma 25(OH)D and studies which administered the intervention through the 
oral route. Among the 1107 studies retrieved, 29 studies met the full inclusion criteria for this 
systematic review. Overall, 8 studies reported significant improvements in the 
endothelial/inflammatory biomarkers/parameters measured. However, in 2 out of the 8 
studies, improvements were reported at interim time points, but improvements were absent 
post-intervention. The remaining 21 trial studies did not show significant improvements in 
the markers of interest measured. Evidence from the studies included in this systematic 
review did not demonstrate that vitamin D supplementation in adults, results in an 
improvement in circulating inflammatory and endothelial function biomarkers/parameters. 
This systematic review does not therefore support the use of vitamin D supplementation as a 
therapeutic or preventative measure for CVD in this respect.  
Key Words: Vitamin D; 25(OH)D; endothelial function; inflammation; flow mediated 
dilation; Randomized controlled trials.  
 
 1. Introduction 
        Vitamin D is a fat soluble secosteroid hormone with both endocrine and autocrine 
functions [1]. The primary endocrine function of vitamin D is the maintenance of calcium 
homeostasis and bone metabolism which is achieved through the modulation of intestinal and 
kidney calcium absorption [2] and reabsorption from the bones [3]. The autocrine function of 
vitamin D depends on genetic transcription unique to the cell type expressing the vitamin D 
receptor (VDR). One such autocrine effect is the modulation of inflammatory pathways 
which play a role in cardiovascular diseases (CVD) amongst others [4, 5].  
        Vitamin D deficiency is defined by a shortage of the active vitamin D metabolite 
calcitriol in target cells [6]. Vitamin D deficiency/insufficiency may raise CVD risk by 
activating a pro-inflammatory cascade which may cause a rise in arterial stiffness and 
endothelial dysfunction, which are well known surrogates of CVD risk [7]. One study which 
compared vitamin D deficient subjects with those in the sufficient range, concluded that 
subjects in the deficient group showed double the risk of myocardial infarction [8].   
Interventions  involving vitamin D supplementation have shown improvement in biomarkers 
of endothelial dysfunction and inflammation, including one intervention which reported a 
significant decrease in the endothelial biomarker E- selectin after administering 300,000 IU 
of vitamin D3 at baseline and eight weeks in 26 non-diabetic patients with chronic kidney 
disease (CKD) [9]. Another study which supplemented with 2000 IU of vitamin D3 over 9 
months in 123 patients with congestive heart failure, reported a significant increase in plasma 
concentrations of the anti-inflammatory cytokine, interleukin 10 (IL-10) [10]. 
       The endothelium plays an important function in maintaining vascular health. It regulates 
vascular tone, and modulates haemostasis and inflammation by several mechanisms. These 
include; the production of nitric oxide (NO) and prostacyclin, which exert anti-aggregatory 
effects on platelets, and the secretion of heparin and protein C/S ( vitamin K- dependent 
plasma proteins) which exert anti-coagulatory or fibrinolytic properties, and the inhibition of 
vascular growth [11,12].   
       To our knowledge, there are currently no systematic reviews investigating whether 
vitamin D supplementation provides an enhanced anti-inflammatory response and improves 
endothelial function. The aim of this review is to evaluate randomized placebo-controlled 
trials investigating the effects of vitamin D on endothelial function and inflammatory markers 
in adults. It is hypothesized that vitamin D supplementation in adults will lead to a reduction 
in circulating inflammatory and endothelial function biomarkers, thereby proposing a 
potential role for vitamin D as an anti-inflammatory therapy for the prevention and treatment 
of CVD.  
 
2. Methods 
2.1 Study selection 
         A systematic literature search of the Cochrane, Pubmed and Medline electronic 
databases was conducted for articles published from 2008 to 2014. The following search 
terms were used to search for relevant publications: “VITAMIN D AND ENDOTHELIAL 
FUNCTION”, “VITAMIN D AND ENDOTHELIAL FUNCTION BIOMARKERS”, 
“VITAMIN D AND CARDIOVASCULAR DISEASE’’, “VITAMIN D AND 
INFLAMMATORY BIOMARKERS’’ and “VITAMIN D AND INFLAMMATORY 
CYTOKINES”. The search was repeated substituting “VITAMIN D” for 
“CHOLECALCIFEROL” for the above search terms. See Fig 1 & Table 1. 
2.2 Inclusion criteria 
Studies were included in the systematic review if they fulfilled the following criteria: 
 Randomized, double-blind, placebo-controlled trials in adult humans. 
 Measure of vitamin D status using serum or plasma 25(OH)D.  
 Supplemented with vitamin D through the oral route of administration (excluding 
fortified drinks and food), as it has been reported that vitamin D administration 
through the oral route produces higher peak 25(OH)D concentrations, and  has a 
longer duration of effect, than the intramuscular route [13]. 
2.3 Exclusion criteria 
Studies were excluded if: 
 Participants were younger than 18 years of age. 
 Vitamin D was also combined with calcium (these were excluded to minimize 
confounding). 
 Studies that used vitamin D analogues. 
2.4 Screening of articles for eligibility 
         Included studies were selected from electronic databases according to the search 
criteria.  Title and abstracts obtained were screened for relevant articles. Articles not relevant 
to the systematic review objectives, outcome of interest, used an alternative study design and 
were duplicate publication and/or were not published in English were discarded.   
2.5 Data collection and extraction 
        The following data was extracted from the selected studies: first author, country and 
year of study, study participants, gender, sample size, baseline 25(OH)D and post 
intervention 25(OH)D concentration, duration and dose of the intervention and baseline and 
post intervention endothelial function outcome measures. The relevant statistically significant 
P values were recorded. The methodological quality of each RCT was assessed using Jadad 
scale for reporting RCTs [14]   .  
2.6 Synthesis of results 
       The results were synthesized by constructing a descriptive summary of the included 
studies in table form (Table 1). The risk of bias was narrated and is based on: randomization, 
blinding and use of a placebo group. Intervention outcome measures are presented as mean ± 
standard deviation (SD). Median values were used for assessment where mean values were 
not reported. For all values, P ≤ 0.05 was considered statistically significant. The PRISMA  
(2009) checklist was followed to structure the systematic review. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow chart of included studies 
PubMed search, Medline search, and Cochrane library search 2008-2014 (n = 1107) 
Potentially relevant studies for further full text screening (n = 53) 
Randomised controlled trials meeting full systematic review criteria (n = 29) 
Unique studies included in the systematic review (n = 29) 
Excluded by abstract and titles (n = 1054) 
12 = supplemented with calcium 
3 = administered via intravenous route 
1 = unblinded 
5 = used vitamin D analogues 
3 = cell studies 
 
 3. Results 
        On initial search of the electronic databases, accessed on 18
th
 July 2014, 1107 articles 
were found. Manuscript titles were reviewed for eligibility, and 1054 articles were excluded 
at this stage. 53 full papers were retrieved for more detailed evaluation. 29 studies met the 
full inclusion criteria, and all of these studies used 25(OH)D to determine the vitamin D 
concentration. Vitamin D herein refers to vitamin D2 and D3 (Figure 1). Whilst some studies 
measured only endothelial (6)
 
or inflammatory parameters (14), the remaining studies 
measured both parameters (9) (Table 1). 
3.1 Studies in type 2 and gestational diabetes mellitus/prediabetic participants 
       Whilst five studies investigated the effect of vitamin D supplementation in type 2 
diabetes mellitus (T2DM) patients [15-18], two studies were performed in prediabetic 
participants [19] and pregnant women with gestational diabetes (GDM) [20]
  
respectively. Of 
these studies, one [15], reported a significant increase of (mean ± SD) 2.35 ± 3.12 % in the 
endothelial function parameters, flow mediated dilation (FMD) from baseline (6.38 ± 4.31 %, 
P = 0.048) (Table1). 
3.2 Studies in participants with a history of CVD 
         Seven studies recruited participants in this category [21-27] of which two reported 
significant improvement in FMD and CRP respectively. In one study, FMD was significantly 
better in the vitamin D group at 8 weeks compared to the placebo group (mean ± SD) 6.9 ± 
3.5 % vs 3.7 ± 3.1 %, P = 0.007), but not at 16 weeks [23]. The second study reported a 
significant decrease in C-reactive protein (CRP, mean ±SD –vitamin D: 1.3 ± 5.4 mg/L vs 
placebo: +2.0 ± 6.8 mg/L, P = 0.03) [25] (Table 1).  
3.3 Studies in participants with CKD 
        Three studies 
 
[28, 29, and 30] were conducted in patients with CKD. The study by 
Alvarez and colleagues [29] reported a significant decrease in monocyte chemo attractant 
protein-1 (MCP-1, mean ± SD) 66.2 ± 2.5 pg/mL – 60.8 ± 2.6 pg/mL, P = 0.02) at 12 weeks 
but not at 52 weeks, whereas the latter study did not observe a significant improvement in the 
endothelial/inflammatory markers measured (Table 1). 
3.4 Studies in overweight/obese participants 
      Two studies  recruited overweight participants and both reported a significant 
improvement in the inflammatory marker TNF-α (mean ± SD) 7.84 ± 3.15 pg/mL - 7.04 ± 
2.25pg/mL, P = 0.049) [31], and FMD (mean ± SD) 54 ± 6s - 43 ± 3s, P = 0.02) [32]    
respectively. Another study [33] in obese participants, did not find significant improvement 
in the inflammatory markers measured (Table 1). 
3.5 Studies in healthy participants 
         Five studies [34-38] recruited healthy participants, amongst these studies, one reported 
a significant improvement in the inflammatory marker hs-CRP (mean ± SD) 4.53 ± 0.64 
µg/ml – 3.12 ± 0.46 µg/ml, P = 0.01) [34]. The remaining four studies did not report 
significant improvements in the markers/parameters measured. 
3.6 Studies in participants with other conditions 
        One study recruited healthy post-menopausal women [39], and did not report significant 
improvements in both endothelial/inflammatory markers measured (Table 1). Four studies 
[40- 43], recruited participants with other diseases such as cystic fibrosis, human 
immunodeficiency virus (HIV), polycystic ovary syndrome and non-alcoholic fatty liver 
disease. Amongst these studies, one study [41], performed in cystic fibrosis patients, found 
significant reduction in an inflammatory marker, TNF- α (mean ± SD) 55.67 ± 8.18 pg/ml - 
27.62 ± 5.82 pg/ml, P < 0.01) (Table 1). 
 
 
 
Table 1. Characteristics of outcome of selected studies 
Study, year, 
Country. 
Participants 
/sample size 
/sex 
Age of 
participants 
(mean ± SD) 
Baseline 25(OH)D 
concentration 
(nmol/l) 
(mean ± SD) 
Post – intervention 
25(OH)D concentration 
(nmol/l) 
(mean ± SD) 
Duration 
(weeks) 
Type and 
dose of 
Vitamin D 
Endothelial/ 
inflammatory 
parameters 
measured 
Jadad 
score 
Effect of intervention on 
outcome measures  
(mean ±SD)  
Sugden et al., 
2008 [15]. 
UK 
 
T2DM 
patients 
n =34 
Sex = M + F 
64.9 ± 10.3 
(Vitamin D 
group) 
63.5  ± 9.5 
(Placebo group) 
 
40.2 ± 10.3 
(Vitamin D group) 
36.4  ± 8.5 
(Placebo group) 
 63.1 ± 26.9 
 (Vitamin D group) 
 44  ± 21 
(Placebo group) 
8  100,000 IU 
single large 
dose of 
vitamin D2 or 
placebo 
FMD 3 Significant increase of 2.35 ± 
3.12 % in FMD from baseline 
of 6.38 ± 4.31% (P = 0.048). 
Zittermann et 
al., 
 2009 [31]. 
Germany 
Overweight/ 
Obese subjects 
 n = 165 
Sex = M + F 
47.4 ± 10.3 
(Vitamin D 
group) 
48.8  ± 10.1 
(Placebo group) 
 
30.0 ± 17.5 
(Vitamin D group) 
30.3  ± 20.1 
(Placebo group) 
85.5 ± 57.5 
(Vitamin D group) 
42.0  ± 35.0 
(Placebo group) 
52 3,332 IU 
vitamin D3 or 
placebo daily 
TNF-α, IL-6 5 Significant decrease in  
TNF-α (7.84 ± 3.15 pg/mL -
7.04 ± 2.25 pg/mL, P = 0.049), 
but not IL-6  (P ˃ 0.05). 
Witham et al.,  
2010 [16]. 
UK 
T2DM 
patients 
n = 58 
Sex = M + F 
65.3 ± 11.1 
100,000 IU 
63.3  ± 9.6 
200,000 IU 
(Vitamin D 
groups) 
66.7 ± 9.7 
(Placebo group) 
41 ± 14  
(100,000 IU) 
48 ± 21 
(200,000 IU)  
(Vitamin D groups) 
45 ± 17 
 (Placebo group) 
8 weeks 
63 ± 20 (100000 IU) 
79 ± 31 (200000 IU) 
(Vitamin D groups) 
54 ± 20 (Placebo group) 
16 weeks  
59 ± 18 (100000 IU) 
76 ± 30 (200000 IU) 
16  Single large 
dose of 
100,000 or 
200,000 IU of 
vitamin D3 or 
placebo 
FMD  5 No change in FMD at both 
100,000 IU and 200,000 IU (P 
> 0.05). 
 (Vitamin D groups) 
53 ± 20  
(Placebo group) 
 
Harris et al., 
2011 [32]. 
USA 
Healthy 
overweight 
African 
Americans 
n =  45 
Sex = M+ F 
 
29 ± 2 
(Vitamin D 
group) 
31  ± 2 
(Placebo group) 
34.3 ± 2.2 
(Vitamin D group) 
38.2  ± 3.0 
(Placebo group) 
100.9 ± 6.6 
(Vitamin D group) 
48.4  ± 3.2 
(Placebo group) 
16  60,000 IU of 
vitamin D3 or 
placebo every 
four weeks 
FMD 4 Significant improvement in 
FMD (54 ± 6s - 43 ± 3s, P = 
0.02). 
Barnes et al.,  
2011 [36]. 
UK 
Healthy young 
and older 
patients 
 n = 413 
211 (aged 20 – 
40y); 
202 (aged ≥ 
64y) 
Sex = M+F 
30.5 ± 6.5 
(200IU) 
30.6 ± 5.5 
(400 IU) 
29.2 ± 6.8 
(600 IU)  
(20-40 years) 
70.7 ± 6.1 
(200 IU); 
70.6 ± 5.4 
(400 IU) 
71.2 ± 4.4 
(600 IU)  
 (≥ 64 years) 
(Vitamin D 
20-40 years 
60.1 (50.0,91.5) 
(200 IU); 
72.2 (53.2- 93.4) 
(400 IU)  
75.9 (55.4 - 89.4) 
(600 IU)  
(Vitamin D groups) 
66.1 (57.2,95.5) 
(Placebo group) 
≥ 64 years 
 51.8 (40.3 -71.3) 
(200 IU); 
55.5 (43.0 -72.3) 
(400 IU) 
20-40 years 
50.4 (45.0 – 60.4) 
(200 IU); 
59.6 (51.3 – 70.3) 
(400 IU) 
69.0 (59.1 -84.4) 
(600 IU); 
 (Vitamin D groups) 
38.9 (30.9,48.1) 
(Placebo group) 
≥ 64 years 
 42.6 (27.8 – 55.9) 
(200 IU) 
70.3 (58.0-81.8) 
(400 IU); 
22  200, 400 or 
600 IU 
vitamin D3 or 
placebo 
hs-CRP, IL-6, 
IL-10 &TNF-α 
5 No effect on the inflammatory 
markers measured (P > 0.05). 
groups) 
29.9  ± 6.5 
(Placebo group) 
55.1 (39.4 – 70.8) 
(600 IU) 
 (Vitamin D 
groups) 
59.1(43.4,78.6) 
(Placebo group) 
 
 
73.9 (61.9 – 90.2) 
(600 IU) 
(Vitamin D groups) 
42.6 (27.8,55.9) 
(Placebo group) 
  
 
Stricker et al.,  
2012 [21]. 
 Switzerland 
Elderly PAD 
patients 
n = 62 
Sex = M+ F 
72.9 ± 8.7 
(Vitamin D 
group) 
74.8  ± 14.6 
(Placebo group) 
 
40.8 ± 16.8 
(Vitamin D group) 
42.5 ± 13.8 
(Placebo group)  
60.8 ± 15.5 
(Vitamin D group) 
43.8  ± 13.8 
(Placebo group) 
4  Single large 
dose of 
100,000 IU 
vitamin D2 or 
placebo 
Skin blood flow, 
hs-CRP, D-
dimer  
4 No significant change in both 
endothelial and inflammatory 
markers  
(P > 0.05) 
Witham et al., 
 2012 [23]. 
UK 
Stroke patients 
n = 55 
Sex = M+F 
66.2 ± 13.0 
(Vitamin D 
group) 
67.7  ± 6.9 
(Placebo group) 
38.7 ± 17.6 
(Vitamin D group) 
37.8  ± 17.8 
(Placebo group) 
54 ± 15 (8 weeks) 
51 ± 22 (16 weeks) 
(Vitamin D group) 
42  ± 21 (8 weeks) 
40  ± 19 (16 weeks) 
(Placebo group) 
 
16  Single large 
dose of 
100,000IU 
vitamin D2 or 
placebo 
FMD 3 FMD significantly better in 
vitamin D group at 8 weeks 
compared to placebo group 
(6.9 ± 3.5% vs 3.7 ± 3.1 %, P = 
0.007), but did not improve at 
16 weeks post intervention (P 
> 0.05). 
Longenecker et 
al., 
2012 [40].  
USA 
HIV Patients 
 n = 44 
Sex = M+F 
47.0 ± 8.0 
(Vitamin D 
group) 
40 ± 10 
(Placebo group) 
Median (range): 
22.5 (17.8 - 32.8) 
 (Vitamin D group) 
15.5 (9.3-24.5) 
(Placebo group) 
Median (range): 35 (- 
15.6 – 51.3) 
(Vitamin D group) 
11 (2 - 24.8) 
(Placebo group) 
12  4,000 IU 
vitamin D3 or 
placebo daily 
FMD, CRP, IL-
6, sTNF-1&2, 
sVCAM-1, 
sICAM-1, 
5 No change in endothelial and 
inflammatory parameters 
measured (P > 0.05). 
  
Sokol et al., 
2012 [22]. 
USA 
CAD patients 
n = 90 
Sex = M+F 
55 ± 9.6 
(Vitamin D 
group) 
56.9  ± 11.6 
(Placebo group) 
 
32.5 ± 17.5 
(Vitamin D group) 
35  ± 17.5 
(Placebo group) 
100 ± 45  
(Vitamin D group) 
37.5  ± 25 
(Placebo group) 
12  50,000 IU 
vitamin D2 or 
placebo 
weekly 
RH-PAT, FRHI,  
E-selectin 
hs - CRP, IL-6, 
IL-12, CXCL-
10,  and IFN-y 
3 No change in inflammatory and 
endothelial parameters 
measured (P > 0.05)   
 
Marckmann et 
al., 
2012 [30] 
Denmark 
Haemodialysis 
(HD) and non-
haemodialysis 
CKD patients 
n = 52 
Sex = M+F 
Median (range): 
71 (62-78) 
(Vitamin D 
group) 
68 (59-76) 
(Placebo group) 
 
HD  
Median (range): 
20.7 (16.3 - 28.9) 
(Vitamin D group) 
35.9 (25.5-45.9) 
(Placebo group)  
Non-HD  
39.3 (17.6 - 50.2)  
(Vitamin D group) 
28.6 (19.4 - 37.8) 
(Placebo group)  
 
HD  
Median (range): 
114.9 (82.5 - 153)  
(Vitamin D group) 
-10.4 (-21.4 to -6.5) 
(Placebo group)  
Non-HD  
127.4 (104.9 - 155.2) 
(Vitamin D group)  
 -7.1 (-12.3 to 9) 
(Placebo group)  
 
8  40,000 IU 
vitamin D3 or 
placebo 
weekly 
vWF, IL-6, 
aPWV, D-dimer 
and CRP 
4 No change in endothelial and 
inflammatory markers 
measured (P > 0.05) 
Grossmann et 
al., 
2012 [41] 
USA 
Cystic fibrosis 
patients 
 n =30 
Sex =M+F 
24.9 ± 16.0 
(Vitamin D 
group) 
28.2 ± 30.9 
(Placebo group)  
76.5 ± 8.0 
(Vitamin D group) 
71.7  ± 8.8 
(Placebo group) 
91.8 ± 6.5 
(Vitamin D group) 
70 ± 10.3 
(Placebo group)  
12  Large bolus 
dose of  250, 
000 IU 
vitamin D3 or 
placebo 
 
TNF-α, IL-6, 
IL-8, IL-10, IL-
1β, IL-18BP and 
NGAL 
5 Significant decrease in TNF-α 
(55.67 ± 8.18 pg/ml - 27.62 ± 
5.82 pg/ml, P < 0.01), but not 
in IL-6,IL-1β, IL-8, IL-10,IL-
18BP and NGAL (P > 0.05). 
          
Witham et al., 
2013 [38]. 
UK 
South Asian 
women living 
in UK 
n = 50 
Sex = F 
41.7 ± 13.4 
(Vitamin D 
group) 
39.4  ± 11.8 
(Placebo group) 
 
 
27 ± 13 
(Vitamin D group) 
27  ± 15 
(Placebo group) 
43 ± 13.0 (4 weeks) 
38 ± 15.0 (8 weeks) 
(Vitamin D group) 
27 ± 17 
(Placebo group)  
8  Single large 
dose of 100, 
000 IU 
vitamin D3 or 
placebo 
FMD, TNF-α, 
IL-6, E-selectin 
5 No change in endothelial and 
inflammatory markers at 4 and 
8 weeks (P > 0.05) 
Witham et al.  
2013 [25]
. 
UK 
Patients with 
history of MI 
n = 74 
Sex = M + F 
64.3 ± 9.8 
(Vitamin D 
group) 
67.5  ± 10.6 
(Placebo group) 
49.0 ± 20.0 
(Vitamin D group) 
45  ± 16 
(Placebo group) 
56 ± 20 (8 weeks) 
62 ± 20 (26 weeks) 
(Vitamin D group) 
45  ± 16 (8 weeks) 
46  ± 16 (16 weeks) 
(Placebo group) 
 
26 Single large 
dose 100,000 
IU vitamin D3 
or placebo at 
baseline, 8 and 
26 weeks. 
TNFα, CRP, 
vWF, RHI and 
E-selectin 
5 Significant decrease in CRP  
 – 1.3 ± 5.4mg/L  (vitamin D 
group) vs +2 ± 6.8 mg/L 
(placebo group), P = 0.03), but 
no improvement TNF-α, vWF, 
RHI, and E-selectin  (P > 0.05) 
Brevlasky et al. 
2013 [17]
.
 
Israel 
T2DM 
patients, 
n = 47 
Sex = M+F 
66.8 ± 9.2 
(Vitamin D 
group) 
65.8  ± 9.7 
(Placebo group) 
 
29.5 ± 27.3 
(Vitamin D group) 
32.3  ± 26.7 
(Placebo group) 
 44 ± 28.8 
(Vitamin D group) 
35  ± 14.8 
(Placebo group) 
52 1,000 IU 
vitamin D3 or 
placebo daily  
hs-CRP 3 No change in hs-CRP  
(P ˃ 0.05) 
Alvarez et al. 
2013 [29].  
USA 
Early CKD 
(stage 2-3) 
patients 
n = 47 
Sex = M+F 
62.5 ± 9.6 67.5 ± 17.5 
(Vitamin D group) 
80  ± 22.5 
(Placebo group) 
77 ± 122 (12 weeks) 
73 ±114 (52 weeks) 
(Vitamin D group) 
-18  ± 19 (12 weeks) 
- 5 ± 19 (52 weeks) 
(Placebo group) 
52   50,000 IU 
vitamin D3 or 
placebo 12 
weeks 
followed by 
50,000 IU 
TNF-α, 
IL-6, MCP-1  
3 Significant decrease in MCP-1 
at 12 weeks  
(66.2 ± 2.5pg/mL – 60.8 ± 
2.6pg/mL, P = 0.02), but not at 
52 weeks. No change in the 
other inflammatory markers 
 every other 
week for 40 
weeks 
 
measured (P > 0.05) 
Wood et al. 
2012 [38]. 
UK 
Post-
menopausal 
women 
 n = 265 
Sex = F 
63.5 ± 1.9  
(400 IU) 
64.1 ± 2.3 
(1000 IU) 
(Vitamin D 
group) 
63.9 ± 2.3 
(Placebo group) 
 
33.3 ± 13.2 (400IU) 
33.4 ±13.9  
(1000 IU) 
(Vitamin D groups) 
36.3  ± 16.4 
(Placebo group) 
64.9 ± 19.8 (400 IU) 
75.7 ± 19.1(1000 IU) 
(Vitamin D groups) 
32.4  ± 14.7 
(Placebo group) 
52 400 or 1,000 
IU vitamin D3 
or placebo 
daily 
hs-CRP, IL-6, 
ICAM-1 
5 No change in inflammatory 
markers measured (P > 0.05). 
Yiu et al. 
2013 [18].  
Hong Kong 
T2DM 
patients 
n = 100 
Sex = M 
65.8  ± 7.3 
(Vitamin D 
group) 
64.9  ± 8.9 
(Placebo group) 
 
52.8 ± 11.0 
(Vitamin D group) 
54.8  ± 10.3 
(Placebo group) 
146.5 (mean) 
(Vitamin D group) 
59.5 (mean) 
(Placebo group) 
12  5,000 IU 
vitamin D3 or 
placebo daily 
FMD, EPC, 
PWV & hs-CRP 
3 No change in both endothelial 
and inflammatory markers 
measured (P > 0.05) 
Witham et al. 
2013 [24] 
UK 
Older patients 
with isolated 
systolic 
hypertension  
n =159 
Sex = M 
 
76.9 ± 4.8 
(Vitamin D 
group) 
76.7  ± 4.5 
(Placebo group) 
45 ± 15 
(Vitamin D group) 
45 ± 15 
(Placebo group) 
69 ±23 (26 weeks) 
67 ±17 at (52 weeks) 
(Vitamin D group) 
52 ±22 at (26 weeks) 
48 ±18 at (52 weeks) 
(Placebo group) 
 
52 100,000 IU 
vitamin D3 or 
placebo every 
3 months 
FMD 5 No change in FMD after 
intervention (P > 0.05) 
 Rahimi-
Ardabili et al. 
2013 [42] 
Iran 
Polycystic 
ovary 
syndrome 
patients 
n =  50 
Sex = F 
 
26.8  ± 4.7 
(Vitamin D 
group) 
27.0  ± 3.7 
(Placebo group) 
17.3 ± 7 
(Vitamin D group) 
18.2  ± 7.3 
(Placebo group) 
58.5 ± 15.4 
(Vitamin D group) 
21.4  ± 9.9 
(Placebo group) 
8  One 50,000IU 
vitamin D3 or 
placebo 
capsules every 
20 days 
hs-CRP 5 No change in hs-CRP  
(P > 0.05) 
 
Sollid et al. 
2014 [19]
 
Norway 
Patients with 
pre-diabetes  
n = 484 
sex = M+F 
 
62.3 ± 8.1 
(Vitamin D 
group) 
61.9  ± 9.2 
(Placebo group) 
59.9 ± 21.9 
(Vitamin D group) 
61.1  ± 21.2 
(Placebo group) 
 
105.7 ± 46.1 
(Vitamin D group) 
64.5  ± 38.1 
(Placebo group) 
52 20,000 IU 
vitamin D3 or 
placebo 
capsules 
weekly 
hs- CRP 5 No change in hs-CRP  
(P > 0.05) 
 
Yusupov et al. 
2010 [37] 
USA 
Ambulatory 
adults 
 n = 120 
Sex 
59.3 ± 13.0 
(Vitamin D 
group) 
58.1  ±13.9 
(Placebo group) 
 
64.3 ± 25.4 
(Vitamin D group) 
63 ± 25.8 
(Placebo group)  
88.5 ± 23.2 
(Vitamin D group) 
95.7  ± 46.1 
(Placebo group)  
13 2,000 IU 
vitamin D3 or 
placebo daily 
IL -
2,4,5,6,8,10,13,
GM-CSF, IFN-
y, TNF-α 
5 No change in cytokines 
measured (P > 0.05) 
Sharifi et al. 
2014 [43] 
Iran 
Patients with 
non-alcoholic 
fatty liver 
disease 
n = 53 
Sex = M+F 
 
40.3 ± 8.7 
(Vitamin D 
group) 
43.9  ± 9.5 
(Placebo group) 
Median (range): 
28.8 (22.0-71.0) 
(Vitamin D group) 
42.1(29.8-62) 
(Placebo group) 
Median (range): 
75 (64.5- 116.5) 
(Vitamin D group) 
48 (36.8 – 66.8) 
(Placebo group) 
 
17 50,000 IU 
vitamin D3 or 
placebo every 
14 days 
hs-CRP, TNF-α 5 No change in inflammatory 
markers (hs- CRP and TNF-α) 
measured (P > 0.05). 
Barker et al. 
2012 [35] 
USA 
Vitamin D 
sufficient 
adults 
n = 30 
Sex = M+F 
26.6 ± 3.2 
(200 IU) 
29 ±5 (4000 IU) 
(Vitamin D 
groups) 
30.2  ± 4.8 
(Placebo group) 
 
36.3 ± 11.3 
(200 IU) 
32.5 ± 6.56 
(4000 IU) 
(Vitamin D groups) 
27.8  ± 10.7 
(Placebo group) 
37.5  ± 8.83 
(200 IU) 
50.1  ± 5.81 
(4000 IU) 
(Vitamin D groups) 
25.1 ± 9.34 
(Placebo group) 
4  200 or 4000 
IU vitamin D3 
or placebo 
daily 
IL-5, IL-10, 
IFN-γ 
2 No change in inflammatory 
markers  
(P > 0.05) 
 
 
     
 
     
Witham et al., 
2010 [26] 
UK 
 
Older patients 
with heart 
failure 
n = 96 
Sex = M+F 
78.8 ± 5.6 
(Vitamin D 
group) 
80.6  ± 5.7 
(Placebo group) 
20.5 ± 8.9 
(Vitamin D group) 
23.7  ± 10 
(Placebo group) 
43.4 ± 30.9 (10 weeks) 
40 ± 22.8  (20 weeks) 
(Vitamin D group) 
26  ± 20.9 (10 weeks) 
25  ± 23.4 (20 weeks) 
(Placebo group) 
 
  
20  100, 000 IU 
vitamin D2 or 
placebo at 
baseline and 
10 weeks 
TNF-α,  5 No change in in TNF-α  
(P > 0.05) 
Asemi et al., 
2013 [34] 
Iran 
Healthy 
pregnant 
women 
n = 48 
Sex = F 
 
 
25.3 ± 4.2 
(Vitamin D 
group) 
24.8  ± 3.6 
(Placebo group) 
44.5 ± 3.3 
(Vitamin D group) 
36.25 ± 3.0 
(Placebo group) 
53.8 ± 4.5 
(Vitamin D group) 
33.25  ± 2.75 
(Placebo group) 
9  400 IU 
vitamin D3 or 
placebo daily 
hs-CRP 5 Significant improvement in hs-
CRP (4.53 ± 0.64 µg/ml – 3.12 
± 0.46 µg/ml, (P = 0.01) 
Wamberg et al., 
2013 [33] 
Denmark 
 
 
 
 
Hewitt et al 
2013 [28] 
Australia 
 
 
 
 
 
 
 
 
Obese adults 
n = 52 
Sex = M + F 
 
 
 
 
CKD-5D 
hemodialysis 
patients 
n = 60 
Sex = M+F 
 
39.5  ± 8.0 
(Vitamin D 
group) 
41.2  ± 6.8 
(Placebo group) 
 
 
Median (range): 
60 (53-71) 
(Vitamin D 
group) 
Median (range): 
67 (54-72) 
(Placebo group) 
 
33.0  ± 10.8 
(Vitamin D group) 
34  ± 9 
(Placebo group) 
 
 
 
45 ± 12.5 
(Vitamin D group) 
40 ± 12.5 
(Placebo group) 
 
 
 
 
 
110.2  ± 21.2 
(Vitamin D group) 
46.8  ± 17.3 
(Placebo group) 
 
 
 
87.5  ±  22.5 
(Vitamin D group) 
40 ± 17.5 
(Placebo group) 
 
26  
 
 
 
 
 
 
26 
7000 IU 
vitamin D3 or  
placebo daily 
 
 
 
 
50,000 IU 
vitamin D3 or  
placebo 
weekly for 8 
weeks, 
followed by 
monthly doses 
for the 
remaining 18 
weeks 
 
hs-CRP, IL-6 
and MCP-1 
 
 
 
 
 
PWV,CRP                   
5 
 
 
 
 
 
 
4           
No change in markers 
measured (P > 0.05) 
 
 
 
 
 
No change in markers 
Measured (P > 0.05) 
 
Abbreviations: AI, augmentation index; ARV, antiretroviral; BNP, B – type natriuretic peptide; CAD, coronary artery disease; CKD, chronic kidney disease; CRP, C-
reactive protein; CXCL-10, C-X-C motif chemokine 10; EFV, Efavirenz; EPCs, endothelial progenitor cells; FMD, flow mediated dilatation; FRHI, Framingham reactive 
hyperemia index; GDM, gestational diabetes mellitus; HD, haemodialysis; HIV, human immunodeficiency virus; hs- CRP, high sensitivity – C-reactive protein; IL, 
interleukin; IFN-γ, interferon gamma; IU, international units; MCP-1, monocyte chemo attractant protein-1;  MI, myocardial infarction; NGAL, neutrophil gelatinase 
associated lipocalin; NR, not reported; PAD, peripheral artery disease; PWV, pulse wave velocity; RHI, reactive hyperaemia index; RCT, randomised controlled trial; RH-
PAT, reactive hyperaemia peripheral arterial tonometry; Sicam-1, soluble intracellular molecule-1; TNF, tumour necrosis factor alpha; T2DM, type 2 diabetes mellitus;  
vWF, von Willebrand factor.  
Discussion 
        To the best of our knowledge, this is the first systematic review aimed at evaluating the 
effect of supplemental vitamin D on endothelial function by examining inflammatory 
biomarkers/parameters in humans. Overall, 8 studies reported significant improvements in the 
biomarkers/parameters measured. However, in 2 out of the 8 studies, improvements were 
reported at interim time points; however, these improvements were absent post intervention. 
Reported improvements were mainly in FMD measurements, but there were no common 
biomarkers that showed an improvement in all the studies (Table 1).  
 
Several mechanisms have been proposed that may account for the reported improvement 
in endothelial and inflammatory biomarkers following vitamin D supplementation. In 2013, 
Kassi et al. [44] suggested that a principal contributory factor to endothelial dysfunction is 
the diminished availability of NO, and the rise in the production of free radicals. Hence, the 
proposed direct mechanism by which vitamin D may improve endothelial function may be by 
enhancing nitric oxide production and decreasing the production of free radicals.  
 
       A study by Molinari et al., [45], examined the effects of vitamin D on NO production 
and p38, Akt, ERK and eNOS phosphorylations in human umbilical vein cell culture 
(HUVEC). It was discovered that vitamin D, acting through its VDR and endothelial NO 
synthase activation, promotes a significant rise in NO production in the endothelium. Another 
proposed mechanism for reported improvement could be, the increase in plasma 25(OH)D 
concentration following vitamin D supplementation. This increase would in turn lead to an 
increase in the intestinal absorption of calcium, which may result in increased intracellular 
calcium, which would in turn stimulate the production of NO, a potent vasodilator purported 
to have protective effects on the endothelium. This is an indirect route by which vitamin D 
increases nitric oxide availability [46].  
 
     A further indirect mechanism by which vitamin D may account for the improved 
endothelial function/inflammatory markers observed in the aforementioned studies may be by 
the way of reducing blood pressure. This is achieved by downregulation of renin and 
angiotensinogen gene expression through a vitamin D response element in the promoter 
region of the renin gene by obstructing the NF-kB pathway
 
[47]. One study, carried out in 
rodents, found that in wild-type mice, inhibition of 1,25-dihydroxyvitamin D3 synthesis by 
adding 2.5% strontium chloride in their normal diet led to an increase in renin expression, 
whereas the injection of vehicle or 30 pmol 1,25(OH)2D3 dissolved in propylene glycol led to 
renin suppression, independent of calcium metabolism [48]. Some of the included study 
participants had T2DM and others were uremic patients. Hence, vitamin D acting through 
VDR may have improved endothelial dysfunction by hindering the damaging effects of 
advanced glycation end products (which have been reported to be increased in diabetic and 
uremic patients) by reducing the expression of genes such as IL-6, and IL-8 involved in the 
advanced glycation end products-activated inflammatory pathway [49].  
 
      The participants in one of the studies which recorded a significant improvement in TNF-
α, were undergoing a weight reduction programme. The loss in weight following this 
programme may, at least in part, be responsible for this improvement, as it has been found 
that adipose tissue expresses TNF- α [50]. 
 
       Most of the included study participants, had disease states which are characterised by 
inflammation. Thus, vitamin D may have played an anti-inflammatory role by repressing NF-
kB activation by enhancing the gene expression of 1kBα in macrophages and peripheral 
blood mononuclear cells, thereby disrupting the movement of upregulated NF-kB subunit p65 
to the nucleus [51]. 
       The majority of studies included in this systematic review however, did not report 
significant improvement in endothelial function following intervention. It may be the case 
that vitamin D supplementation may in fact not elicit clinical/health effects, however, several 
explanations are possible for the lack of effect of vitamin D supplementation in many of the 
included studies.  
One study recruited a population at risk of vitamin D deficiency such as post-menopausal 
women. At menopause there is a transition in vitamin D requirements, as the VDR depends 
on oestrogen which declines with age [52, 53]. As the number of VDR decreases following a 
reduction in oestrogen, this leads to alterations in the quantity and functionality of the VDR 
in target tissues [54]. Target cell response to vitamin D is dependent on VDR levels and 
factors such as glucocorticoids and retinoids as well as oestrogen, are known to modulate 
VDR levels [55]. This is supported by evidence from studies in animal models (rats), that 
shows oestrogen increases the expression of VDR in various tissues such as endothelial, 
colon, immune and smooth muscle cells [56, 57].  It could therefore be assumed that at 
menopause, which is characterised by a reduction in oestrogen, there will be a decrease in 
VDR, which in turn may explain a lack of improvement in both endothelial and inflammatory 
biomarkers/ parameters measured. The use of a higher (e.g. 5,000 IU and above) daily dose in 
populations at risk of vitamin D deficiency and in individuals with 25(OH)D levels below 
55nmol/l is recommended, as this has previously produced  significant improvement in  
vitamin D status in participants with particularly low levels of 25(OH)D [58, 59]. 
Several included studies, recruited participants with established CVD who were taking 
statins and anti-hypertensive drugs. Vitamin D is a derivative of cholesterol, and statins lower 
serum cholesterol concentration by inhibiting HMG CoA reductase, the rate limiting enzyme 
in cholesterol synthesis. Therefore, by reducing cholesterol synthesis, statins also interfere 
with vitamin D metabolism [60, 61].  The interaction between vitamin D and the drugs taken 
by participants in these studies may also be significant as they may affect vitamin D 
metabolism by competing for CYP3A4 enzyme activity. Amongst the six cytochrome P450 
enzymes that catalyse reactions involved in the metabolism of up to 90% of therapeutic 
drugs, CYP3A4 and CYP2D6 are most important [62]. CYP3A4 is a hepatic 25-hydroxylase 
enzyme that converts inactive to active vitamin D, and is also responsible for the metabolism 
of antihypertensive drugs along with some statins such as Atorvastatin, Lovastatin and 
Simvastatin. These drugs are CYP3A4 enzyme inhibitors, and therefore all compete for the 
same enzyme receptor site, with the more potent drug dominating. This results in a decreased 
metabolism of the competing drug which is vitamin D in this case, therefore reducing its 
efficacy. This could explain the slight increase in serum 25(OH)D despite the large vitamin D 
doses administered. The studies in which participants were taking statins didn’t state the 
exact type of statins they were using, which is significant as only statins metabolised by 
CYP3A4 can interact with vitamin D [63-65]. 
       Some participants in the included studies already had established and widespread CVD, 
this could have led to irreversible anatomical changes in the vascular wall, enough to prevent 
positive impact of the active treatment. Genetic variation (polymorphism) of CYP3A4 may 
influence an individual’s response to vitamin D [66]. Old age is a contributing factor to 
individual variation in vitamin D metabolism and some of the included study participants 
were older adults. The cytochrome P450 monooxygenase system is more affected by aging 
than by any other metabolic pathway due to a reduction in enzyme activity, hepatic blood 
flow and liver mass result in a decreased metabolic activity [67]. 
       One study included in this review recruited HIV patients  [40] who were undertaking 
stable antiretroviral therapy. There could be increased catabolism of vitamin D in this study, 
as increased intake of the antiretroviral drug Efavirenz (EFV), has been reported by Childs et 
al., [68]
  
to reduce the expression of CYP2RI, an enzyme involved in the 25- hydroxylation of 
vitamin D3, and also induce  the expression of CYP24  which converts vitamin D into its 
inactive metabolite. 
Limitations of the present systematic review are acknowledged in that only RCTs were 
included, which are known to provide more reliable data by reducing the possibility of 
confounding or selection bias. The included RCTs only supplemented with vitamin D, and 
excluded RCTs which supplemented with both calcium and vitamin D to allow adequate 
conclusions on the effect of vitamin D to be drawn. However, it is acknowledged that there is 
also some heterogeneity between studies, as study populations were diverse, with different 
diseases, follow-up duration and vitamin D doses; the majority of which were administered as 
single large, monthly and weekly doses. The vitamin D doses administered in some of the 
studies included were insufficient to cause an overall change in the inflammatory/endothelial 
markers measured. Some studies used healthy participants and therefore the elevated levels of 
inflammatory markers that were seen in participants with CVD were absent. 
In conclusion, this systematic review did not on the whole, demonstrate that vitamin D 
supplementation in adults leads to improved circulating inflammatory and endothelial 
function biomarkers/parameters. It can therefore be concluded that based upon this systematic 
review, a strong rationale does not yet exist for the therapeutic administration of 
supplemental vitamin D in order to attenuate CVD risk. It is also possible that the anti–
inflammatory role of vitamin D may not occur at the systemic level but instead occur at the 
cellular level. Furthermore, many studies in relation to vitamin D, have used CVD risk as a 
secondary outcome and therefore may not be sufficiently powered in relation to CVD 
endpoints. 
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